2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes

Saved in:
Bibliographic Details
Published inJournal of the American College of Cardiology Vol. 76; no. 9; pp. 1117 - 1145
Main Authors Das, Sandeep R., Everett, Brendan M., Birtcher, Kim K., Brown, Jenifer M., Januzzi, James L., Kalyani, Rita R., Kosiborod, Mikhail, Magwire, Melissa, Morris, Pamela B., Neumiller, Joshua J., Sperling, Laurence S.
Format Journal Article
LanguageEnglish
Published Elsevier Inc 01.09.2020
Subjects
ACC Expert Consensus Decision Pathway
atherosclerotic cardiovascular disease
cardiovascular risk reduction
diabetes
GLP-1RA
SGLT2 inhibitor
type 2 diabetes
type 2 diabetes
GLP-1RA
atherosclerotic cardiovascular disease
cardiovascular risk reduction
diabetes
SGLT2 inhibitor
ACC Expert Consensus Decision Pathway
Online AccessGet full text

Cover

More Information
Bibliography:Ashleigh Covington, MA, Team Leader, Clinical Pathways and Heart House Roundtables Amelia Scholtz, PhD, Publications Manager, Science & Quality, Education, and Publications
Joseph M. Allen, MA, Team Leader, Clinical Standards and Solution Sets
Amy Dearborn, Team Leader, Clinical Content Development
Athena Poppas, MD, FACC, President Cathleen C. Gates, Interim Chief Executive Officer John Rumsfeld, MD, PhD, FACC, Chief Science & Quality Officer
PRESIDENT AND STAFF
ISSN:0735-1097
1558-3597
DOI:10.1016/j.jacc.2020.05.037